Luteal Phase Defect
10
1
1
8
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
40%
4 trials in Phase 3/4
0%
0 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 8 completed trials
Clinical Trials (10)
Luteal Support in Artificial Vitrified/Warmed Cycles With Low Progesterone
Luteal Phase Support in IUI MOH Treatment Luteal Phase Support in IUI MOH Treatment
Luteal Support in Frozen-Thawed Embryo Transfer Cycles
Energy Restriction and Hormones in Premenopausal Women
Bioenergetics of Exercise-Induced Menstrual Disturbances
Progesterone Levels and Clinical Outcomes Using a Single Pessary of 400 mg of Vaginal Progesterone in Substitutive Cycles for Embryo Transfer.
Luteal Phase Support In IVF Women Using GnRH Agonist
Effects of Varied Estrogen Doses on Endometrial Receptivity
Progesterone in Luteal Phase Deficiency
Dydrogesterone Versus Intravaginal Progesterone in the Luteal Phase Support